Her research focuses on thrombosis, haemostasis and coagulation. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. The company has now placed another proprietary biopharmaceutical (idarucizumab) on the European and American markets and has a proprietary pipeline of monoclonal antibodies in late clinical development phases. The company’s last propriety biotech drug (tenecteplase) received marketing authorisation in 2001. National Library of Medicine.Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived at the Wayback Machine, American Medical Association."International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". Food and Drug Administration (FDA) (Press release). ^ "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa".^ Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al.^ a b c "Praxbind- idarucizumab injection".^ "Praxbind 2.5 g/50 mL solution for injection/infusion - Summary of Product Characteristics (SmPC)".^ "Prescription medicines: registration of new chemical entities in Australia, 2016".
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |